Ascending Dose Study of CT1812 in Healthy Volunteers

NCT02570997 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Cognitive Impairment

Interventions

DRUG: CT1812
DRUG: Placebo

Sponsor

Cognition Therapeutics